This meeting took place in 2012

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)

Organizer(s) Sam Gandy, Steven T. DeKosky and Ann C. McKee
February 26—March 2, 2012
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 26, 2011
Late Abstract Deadline: Dec 2, 2011
Scholarship Deadline: Oct 26, 2011
Early Registration Deadline: Jan 4, 2012

Supported by the Directors’ Fund

Summary of Meeting:
Acute traumatic brain injury (TBI) and its long-term neurodegenerative complications (known collectively as chronic traumatic encephalopathy, or CTE) are increasingly recognized as major public health issues, especially in the context of sports-related head injury and battlefield blast (military) exposure. Awareness of these issues has risen as neurological, psychiatric and neurodegenerative phenomena are associated with professional athletes and with veterans returning from Iraqi and Afghan theaters. The physics of head injury, as well as the epidemiological and neuropsychiatric aspects of sports-related and blast-related syndromes, will be reviewed in the initial sessions of this three-day meeting. Advances in functional neuroimaging and in the rapid and convenient determination of peptides and proteins in the cerebrospinal fluid and plasma will be reviewed in terms of their possible pathobiological significance as well as their identities as possible biomarkers. Later sessions will focus on the overlap between CTE and major neurodegenerative diseases, such as Alzheimer’s Disease (AD), frontotemporal dementia and amyotrophic lateral sclerosis. CTE is associated with accumulation of aggregated proteins or protein fragments, including tau, TDP-43, the Alzheimer’s amyloid precursor protein (APP) and the APP metabolite, amyloid-b. New experimental therapeutics research targets the roles these abnormal protein structures play in injury severity and subsequent outcome. Ab-lowering medications, currently in clinical trials for AD, improve outcome following acute brain trauma in rodent models, suggesting a pathway toward potential therapeutic interventions. Because apolipoprotein E (ApoE) isotype is an important determinant of outcome from acute severe as well as mild repetitive TBI, this meeting coincides in time and venue with the Keystone Symposia meeting on ApoE, Alzheimer’s and Lipoprotein Biology. Opening plenary sessions and an optional fourth day of sessions are available for those interested in learning more about basic biology and/or clinical interventions related to APOE.

View Meeting Program


National Institute of Neurological Disorders and Stroke (NINDS) Scholarship Recipients

Mario Ganau
University of Cagliari, Italy

Sarah C. Hellewell
National Trauma Research Institute, Monash University, Australia

Andrei Irimia
University of California, Los Angeles, USA

Victoria E. Johnson
University of Pennsylvania, USA

Theresa Currier Thomas
University of Kentucky, USA